12 June 2018

Important industry talks at ASCO 2018 and Bio International

Comment by Mike Jagielski, President & CEO of KCR

Last week was very engaging for the life science industry, as there were two important events taking place in the U.S.: 2018 ASCO Annual Meeting and BIO International Convention (BIO 2018).

Mike Jagielski, commented: 'For me as a CEO of KCR, a contract research organization, ASCO is a great gathering to catch up with our clients about their ongoing projects and future needs. It is also a good place to 'feel the industry mood'. There is still plenty of momentum ahead of the oncology research, although we also witness that not every approach will eventually lead to a success considering the series of IDO inhibitors trial setbacks, including Incyte's drug candidate epacadostat and its failed phase 3 trial.

Oncology surely will continue to play a dominant role in R&D for pharma and biotech industries, however, it is probably also time to watch out the next therapeutic area, which might soon gain similar momentum. Central Nervous System (CNS) would be certainly high on the list. I am very much looking forward to the next year event, as I am sure that ASCO 2019 will bring new scientific highlights.”

From the left: Mike Jagielski, CEO of KCR, Monika Dudzisz-Sledz, Medical Monitor, Michael Forte, Director, Clinical Trial Solutions, KCR, at ASCO 2018.

BIO International Convention was another event, which brought a lot of opportunities for intensive networking and updates in wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

“I attended BIO International for the first time, as the date never seemed to work in the past,” said Mike Jagielski. “This year the gathering was in Boston, so as we have KCR office here, attending BIO 2018 was an easy choice. So, having this experience, I must admit that it is a great stage for the international biotech community to network, and look for new cross-country partnerships and investments. The organizers did a great job also by setting-up a perfect scientific framework. I had a chance to attend a few sessions, such as a 'Global view on the vaccine R&D', which I found quite fitting, as we are currently conducting a large-scale vaccine project. Of course, for us it was also a great occasion to catch up with our non-US clients. “

KCR is present at main industry events in Europe as well as the U.S. Please check the upcoming events here. To set up a meeting, please contact us at pr@kcrcro.com.

KCR is a Contract Research Organization (CRO) providing clinical development solutions for the pharmaceutical, biotechnology and medical device industries. The company supports clients with full-service capabilities across three main services: Trial Execution (TE), Functional Service Provision (FS) and Late Phase (LP) over a broad range of therapeutic areas. KCR operates across four main regions: North America (NA), Western Europe (WE), Central Europe (CE) and Eastern Europe (EE) with hubs located in Boston, US, Berlin, Germany, Warsaw, Poland and Kiev, Ukraine respectively. The company’s geographical set up suits perfectly to deliver optimized trial execution strategies for life-changing therapies. For more information, visit www.kcrcro.com.

KCR: We see human behind every number.

Media Contact

Joanna Lewandowska
Associate Director, PR & Marketing
mobile: (+48) 605 053 164
pr@kcrcro.com